PNC Financial Services Group Inc. Purchases 3,225 Shares of AstraZeneca PLC (NASDAQ:AZN)

PNC Financial Services Group Inc. grew its holdings in AstraZeneca PLC (NASDAQ:AZN) by 1.4% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 234,341 shares of the company’s stock after acquiring an additional 3,225 shares during the quarter. PNC Financial Services Group Inc.’s holdings in AstraZeneca were worth $15,783,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. Anchor Investment Management LLC acquired a new position in shares of AstraZeneca during the 4th quarter worth approximately $26,000. Compagnie Lombard Odier SCmA acquired a new stake in AstraZeneca during the fourth quarter worth approximately $27,000. Nemes Rush Group LLC increased its stake in AstraZeneca by 375.6% during the 3rd quarter. Nemes Rush Group LLC now owns 428 shares of the company’s stock worth $29,000 after acquiring an additional 338 shares during the period. Northwest Financial Advisors acquired a new position in AstraZeneca in the 4th quarter valued at $34,000. Finally, Atlantic Edge Private Wealth Management LLC bought a new stake in shares of AstraZeneca during the 4th quarter valued at $35,000. 20.35% of the stock is currently owned by institutional investors and hedge funds.

AstraZeneca Price Performance

Shares of NASDAQ AZN opened at $79.18 on Wednesday. The company has a market capitalization of $245.49 billion, a PE ratio of 38.81, a P/E/G ratio of 1.39 and a beta of 0.47. The company has a quick ratio of 0.70, a current ratio of 0.89 and a debt-to-equity ratio of 0.73. The firm has a fifty day simple moving average of $71.11 and a 200 day simple moving average of $67.48. AstraZeneca PLC has a twelve month low of $60.47 and a twelve month high of $79.25.

AstraZeneca (NASDAQ:AZN) last released its quarterly earnings data on Thursday, April 25th. The company reported $1.03 earnings per share for the quarter, beating the consensus estimate of $0.95 by $0.08. The company had revenue of $12.68 billion during the quarter, compared to analyst estimates of $11.92 billion. AstraZeneca had a net margin of 13.30% and a return on equity of 30.42%. On average, sell-side analysts forecast that AstraZeneca PLC will post 4.04 EPS for the current year.

Wall Street Analyst Weigh In

Several research firms recently weighed in on AZN. Deutsche Bank Aktiengesellschaft raised shares of AstraZeneca from a “sell” rating to a “hold” rating in a research report on Tuesday, April 16th. Morgan Stanley assumed coverage on shares of AstraZeneca in a research report on Tuesday, January 23rd. They set an “overweight” rating on the stock. Finally, BMO Capital Markets boosted their price objective on shares of AstraZeneca from $80.00 to $82.00 and gave the company an “outperform” rating in a research report on Friday, April 26th. Three research analysts have rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $81.00.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.